RE:RE:RE:RE:RE:RE:RE:90 daysune 01, 2023 - atezolizumab cancer research focus.
This is the list of Roche's development activity with atezolizumab with the highlighted cancers having relevance to tecentriq in combination with ONCY's pelareorep.
Atezolizumab (RG7446) is under development for the treatment of poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC), recurrent glioblastoma, gliosarcoma, recurrent and metastatic esophageal squamous cell carcinoma, advanced follicular lymphoma, advanced rectal cancer, metastatic neuroendocrine tumor of the lung, metastatic hepatocellular carcinoma, chronic myeloid leukemia, head and neck cancer squamous cell carcinoma including oropharynx, oral cavity, larynx, or hypopharyngeal cancers, advanced cutaneous squamous cell carcinoma, metastatic breast cancer, advanced esophageal squamous cell carcinoma, relapsed, refractory and treatment-naive acute myeloid leukemia, brain metastasis, locally advanced or metastatic solid malignancies, thymic cancer, treatment-naive non-metastatic cutaneous melanoma, metastatic hepatocellular carcinoma, recurrent glioblastoma multiforme (GBM), metastatic breast cancer and HER positive and PD-L1 positive breast cancer, mycosis fungoides and sezary syndrome patients associated cutaneous T-cell lymphoma, triple-negative breast cancer, early breast cancer, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, metastatic melanoma, cutaneous t-cell lymphoma, recurrent, metastatic pancreatic ductal adenocarcinoma, advanced/recurrent endometrial cancer, chronic myelomonocytic leukemia, metastatic mucosal melanoma, persistent and metastatic cervical cancer, head and neck squamous cell carcinoma, small cell lung cancer (first line therapy, relapsed or refractory), glioblastoma, anaplastic thyroid carcinoma, soft tissue sarcoma including liposarcoma, penile cancer, leiomyosarcoma, myxofibrosarcoma, undifferentiated pleomorphic sarcoma (UPS), angiosarcoma, translocation sarcoma, uterine cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, squamous and non-squamous non-small cell lung cancer PDL-1 selected patients, muscle invasive bladder cancer, appendiceal adenocarcinoma, pleural mesothelioma, pancreatic neuroendocrine tumor, merkel cell carcinoma, non muscle invasive bladder cancer, anal cancer, metastatic colorectal cancer, metastatic melanoma, idiopathic pulmonary fibrosis, metastatic renal cell carcinoma, renal medullary carcinoma, malignant rhabdoid tumor, atypical teratoid rhabdoid tumor, Poorly differentiated chordoma, Epithelioid sarcoma, muscle invasive urothelial cancer , Other SMARCB1 or SMARCA4 deficient tumors and metastatic non-small cell lung cancer as second and third line therapy.